OBJECTIVE： To compared with empirical medication and medication under the guidance of adenosine triphosphate-tumor chemosensitivity assay （ATP-TCA） in the treatment of platinum resistance recurrent ovarian cancer， and to explore clinical efficacy， survival situation of the occurrence of ADR. METHODS： 90 cases of platinum resistant recurrent ovarian cancer were divided into drug sensitive group （46 cases） and control group （44 cases） according to admission order. According to clinical experience， control group was given gemcitabine+ifosfamide+doxorubicin for chemotherapy； according to the ATP-TCA test results， chemotherapy plan of drug sensitive group was determined. A treatment course of 2 groups lasted for 28 d， and both received 2-6 courses of chemotherapy. Chemotherapy efficacy， survival situation and the occurrence of ADR were compared between 2 groups. RESULTS： 18 cases receiving paclitaxel， 14 cases receiving doxorubicin， 6 cases paclitaxe+vinorelbine， 5 cases gemcitabine， 3 cases topotecan in the drug sensitive group. The total effective rate of drug sensitive group was 58.70％， which was significantly higher than that （36.96％） of control group， with statistical significance （P＜0.05）. The progression free survival and median survival of drug sensitive group were significantly longer than those of control group， and half year survival rate and 1-year survival rate were higher than control group， with statistical significance （P＜0.05）. The incidence of ADR was 82.61％ in drug sensitive group and 80.43％ in control group， without statistical significance （P＞0.05）. CONCLUSIONS： According to ATP-TCA test results， chemotherapy efficacy and survival situation of patients with platinum resistant recurrent ovarian cancer receiving targeted chemotherapy regimen are better than those receiving clinical empirical medication， and the incidence of ADR will not be influenced.